- ￥3900
- biorbyt
- 78.13-5000 pg/mL
- 30.2 pg/mL
- orb1817319
- 英国
- 2026年01月21日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
999
- 供应商：
biorbyt
- 检测范围：
78.13-5000 pg/mL
- 检测方法：
Sandwich
- 适应物种：
Mouse
- 样本：
Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 灵敏度：
30.2 pg/mL
- 规格：
48 T
产品别名：CXCL3; SCYB3; GRO3; GRO-G; MIP2-B; MIP2b; CINC2b; CINC2b; Chemokine(C-X-C-Motif)ligand 3; Macrophage inflammatory protein 2-beta
应用笔记：standard: 5000 pg/mL. Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse GROγ. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse GROγ. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse GROγ, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse GROγ in the samples is then determined by comparing the OD of the samples to the standard curve
实验时长：3.5h
Note：For research use only.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Characterization and Validation of Cre‐Driver Mouse Lines
recombination in diverse tissues by a tamoxifen‐inducible form of Cre: A tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 244:305‐318. Indra, A.K
Developing Genetically Engineered Mouse Models to Study Tumor Suppression
models. Oncogene 26:2177‐2184. Jacks, T., Fazeli, A., Schmitt, E.M., Bronson, R.T., Goodell, M.A., and Weinberg, R.A. 1992. Effects of an Rb mutation in the mouse. Nature 359
observation of leukaemic events due to gamma retroviral vector insertion and activation of the LMO-2 proto-oncogene in patients enrolled in the French and British gene therapy trials for X-SCID demonstrates the need to understand vector associated genotoxicity
